FOXP2 confers oncogenic effects in prostate cancer

Identification oncogenes is fundamental to revealing the molecular basis of cancer. Here, we found that FOXP2 is overexpressed in human prostate cancer cells and prostate tumors, but its expression is absent in normal prostate epithelial cells and low in benign prostatic hyperplasia. FOXP2 is a FOX transcription factor family member and tightly associated with vocal development. To date, little is known regarding the link of FOXP2 to prostate cancer. We observed that high FOXP2 expression and frequent amplification are significantly associated with high Gleason score. Ectopic expression of FOXP2 induces malignant transformation of mouse NIH3T3 fibroblasts and human prostate epithelial cell RWPE-1. Conversely, FOXP2 knockdown suppresses the proliferation of prostate cancer cells. Transgenic overexpression of FOXP2 in the mouse prostate causes prostatic intraepithelial neoplasia. Overexpression of FOXP2 aberrantly activates oncogenic MET signaling and inhibition of MET signaling effectively reverts the FOXP2-induced oncogenic phenotype. CUT&Tag assay identified FOXP2-binding sites located in MET and its associated gene HGF. Additionally, the novel recurrent FOXP2-CPED1 fusion identified in prostate tumors results in high expression of truncated FOXP2, which exhibit a similar capacity for malignant transformation. Together, our data indicate that FOXP2 is involved in tumorigenicity of prostate.

[1]  Zekuan Xu,et al.  The novel role of circular RNA ST3GAL6 on blocking gastric cancer malignant behaviours through autophagy regulated by the FOXP2/MET/mTOR axis , 2022, Clinical and translational medicine.

[2]  Yajun Liu,et al.  AGAP2-AS1/miR-628-5p/FOXP2 feedback loop facilitates the growth of prostate cancer via activating WNT pathway. , 2021, Carcinogenesis.

[3]  G. Pond,et al.  Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. , 2020, European urology oncology.

[4]  Hongbing Shen,et al.  Remote modulation of lncRNA GCLET by risk variant at 16p13 underlying genetic susceptibility to gastric cancer , 2020, Science Advances.

[5]  Sung-Hoon Kim,et al.  Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression , 2019, Molecular Cancer.

[6]  Hatice S. Kaya-Okur,et al.  CUT&Tag for efficient epigenomic profiling of small samples and single cells , 2019, Nature Communications.

[7]  Zijie Sun,et al.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate , 2018, The Journal of Biological Chemistry.

[8]  L. Trusolino,et al.  Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy , 2018, Nature Reviews Cancer.

[9]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[10]  F. Saad,et al.  Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[12]  David C. Smith,et al.  Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer , 2016, Neoplasia.

[13]  Daowen Wang,et al.  Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice. , 2015, Gastroenterology.

[14]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[15]  Christian Veltkamp,et al.  A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer , 2014, Nature Genetics.

[16]  M. Bhasin,et al.  MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. , 2014, Cell stem cell.

[17]  Michael V. Gormally,et al.  Suppression of the FOXM1 transcriptional program via novel small molecule inhibition , 2014, Nature Communications.

[18]  Wei Zhou,et al.  Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. , 2014, Cancer research.

[19]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[20]  G. Sauter,et al.  Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers , 2013, Journal of Clinical Pathology.

[21]  M. Loda,et al.  ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. , 2013, Genes & development.

[22]  J. Michael Bowers,et al.  Foxp2 Mediates Sex Differences in Ultrasonic Vocalization by Rat Pups and Directs Order of Maternal Retrieval , 2013, The Journal of Neuroscience.

[23]  Jun Wang,et al.  SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data , 2013, Genome Biology.

[24]  Zohar Mukamel,et al.  Regulation of MET by FOXP2, Genes Implicated in Higher Cognitive Dysfunction and Autism Risk , 2011, The Journal of Neuroscience.

[25]  Kay E. Davies,et al.  Foxp2 Regulates Gene Networks Implicated in Neurite Outgrowth in the Developing Brain , 2011, PLoS genetics.

[26]  J. Christensen,et al.  Efficacy of c-Met inhibitor for advanced prostate cancer , 2010, BMC Cancer.

[27]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[28]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[29]  Siu-Ming Yiu,et al.  SOAP2: an improved ultrafast tool for short read alignment , 2009, Bioinform..

[30]  T. Borodina,et al.  Transcriptome analysis by strand-specific sequencing of complementary DNA , 2009, Nucleic acids research.

[31]  Huanming Yang,et al.  SNP detection for massively parallel whole-genome resequencing. , 2009, Genome research.

[32]  Johannes Schwarz,et al.  A Humanized Version of Foxp2 Affects Cortico-Basal Ganglia Circuits in Mice , 2009, Cell.

[33]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[34]  Sridhar Hannenhalli,et al.  The evolution of Fox genes and their role in development and disease , 2009, Nature Reviews Genetics.

[35]  Constance Scharff,et al.  FOXP2 as a molecular window into speech and language. , 2009, Trends in genetics : TIG.

[36]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[37]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[38]  D. Geschwind,et al.  Identification of the transcriptional targets of FOXP2, a gene linked to speech and language, in developing human brain. , 2007, American journal of human genetics.

[39]  D. Geschwind,et al.  High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in speech and language disorders. , 2007, American journal of human genetics.

[40]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[41]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[42]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Christensen,et al.  A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells , 2004, Clinical Cancer Research.

[44]  K. Nakashiro,et al.  Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. , 2003, Oncology reports.

[45]  Todd R. Golub,et al.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[47]  A. Monaco,et al.  A forkhead-domain gene is mutated in a severe speech and language disorder , 2001, Nature.

[48]  Weiguo Shu,et al.  Characterization of a New Subfamily of Winged-helix/Forkhead (Fox) Genes That Are Expressed in the Lung and Act as Transcriptional Repressors* , 2001, The Journal of Biological Chemistry.

[49]  R. Matusik,et al.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.

[50]  A. Bardelli,et al.  A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth* , 1999, The Journal of Biological Chemistry.

[51]  J. Claverie,et al.  The significance of digital gene expression profiles. , 1997, Genome research.

[52]  M. Webber,et al.  Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. , 1997, Carcinogenesis.

[53]  P. Humphrey,et al.  Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. , 1995, The American journal of pathology.

[54]  P. Troncoso,et al.  c-met proto-oncogene expression in benign and malignant human prostate tissues. , 1995, The Journal of urology.

[55]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[56]  A. Jemal,et al.  Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. , 2019, European urology.

[57]  M. Salto‐Tellez,et al.  Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[58]  M. Hofmann,et al.  At the Met , 2017 .

[59]  Shujia Huang,et al.  Systematic assessment of reduced representation bisulfite sequencing to human blood samples: A promising method for large-sample-scale epigenomic studies. , 2012, Journal of biotechnology.

[60]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[61]  Claude-Alain H. Roten,et al.  Theoretical and practical advances in genome halving , 2004 .

[62]  C. Cooper.  The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor. , 1992, Oncogene.